Interestingly, recent data from INVOKE-2 phase II study revealed a marked increase in ARIA events after TREM2-agonist antibody treatment [10], suggesting that activation of macrophage lineage cells without directly engaging amyloid deposits is sufficient to trigger ARIA in AD patients. This evidence concerns the gene TREM2 and Alzheimer disease.